GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Action(s) initiated or orders passed
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has received an order dated 17 February 2026 from the Additional Commissioner of CGST & Central Excise, Mumbai Central, for the period April 2022 to March 2023. The order raises a total demand of Rs. 6.93 crore, comprising Rs. 3.46 crore in tax and Rs. 3.46 crore in penalty, with interest not yet quantified. The demand relates to alleged non-payment of GST on the export of services in Maharashtra. The order was received physically on 20 February 2026 and has not yet been uploaded on the GST portal. The company has stated there is no impact on its financial operations and that it will take appropriate action, which typically means filing an appeal.
The Rs. 6.93 crore demand is small relative to GSK Pharma's overall size and the company says it will contest it, so the near-term impact on shareholders is likely limited. However, if the demand is upheld after appeal, it could become an additional outflow and is a reminder of ongoing tax-related risks in the business.